Hi all,
When you compare the efficacy data from the Phase 1 SNT-5505 trial on MF and then look at it's combination outcome with Ruxolitinib, a JAK inhibitor, you get a clear hint on what to expect in the next few days .
Have a look SNT quarterly 30/07 to gain an insight of the P1 efficacy data.
Ruxolitinib has 256,233 safety years of data on cumulative patients so roughly ten years patient exposure.
We have the data to explain what it does for patients. Very soon we will have a combination drug for a 1 billion per year turnover.
No wonder SNT are nervous. The data has been coming in since approximately May this year. Still needs a peer review before the conference. Why because the data is so good.
Have a look at Hashan De Silva on LinkedIn. His last post and his third last post. (Non Executive Director SNT)
I am content on this play.
Cant wait to get the interim results to do my own peer review and post same .
Kpax
Add to My Watchlist
What is My Watchlist?
